StreetAlpha.app
Home › Stocks › OMER

Omeros Corp (OMER)

Healthcare
$13.92
▼ −16.55%
LAST CLOSE · NOV 17

Omeros is a Seattle biotechnology company that develops drugs targeting the complement system, including its approved treatment YARTEMLEA. It last closed at $13.92 on Nov 17, down 16.55% on the day. OMER last reported earnings on Mon, Nov 16, 2026. Over the past 90 days StreetAlpha recorded 1 whale options trade in OMER, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is OMER in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
$98.4M
EPS (diluted)
$1.55
Free cash flow
−$37.0M
Valuation
Market cap
$1.0B
74.5M shares
P/E
9.0
Price over 12 month EPS
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.1M
At Sep 30
Shareholder equity
−$90.0M
Buybacks
$9.9M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $194.2M$194.2MFY2021FY2022: $47.4M$47.4MFY2022FY2023: −$117.8M−$117.8MFY2023FY2024: −$156.8M−$156.8MFY2024FY2025: −$3.4M−$3.4MFY2025

From OMER's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · After the close (AMC)
Reported EPS
$0.02
vs -$0.27 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±13.8%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated OMER in the past 90 days, not enough for a consensus
Average 12-month target
$22.00
▲ 58.0% upside

Based on 1 analyst who set a price target on OMER in the past 90 days. The average target is $22.00, with a high of $22.00 and a low of $22.00, compared with the last close of $13.92.

$8$13$18$23PAST 14 TRADING DAYS12-MONTH TARGETSHIGH $22AVG $22LOW $22May 27LAST CLOSE+12 MO$8$13$18$23PAST 14 DAYSTARGETSHIGH $22AVG $22LOW $22May 27LAST CLOSE+12 MO
Highest target$22.00
Average target$22.00
Lowest target$22.00
Latest rating changes
Cantor FitzgeraldReiterated
Oct 14Buy$22
Cantor FitzgeraldUpgrade
Sep 22Buy$22
HC Wainwright & Co.Maintained
Jun 26Buy$33
DateFirmActionRatingPrice target
Oct 14Cantor FitzgeraldReiteratedBuy$22
Sep 22Cantor FitzgeraldUpgradeBuy$22
Jun 26HC Wainwright & Co.MaintainedBuy$33
Loading…

Technical Analysis

OMER · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold

The stock is 24% below its 20 day and 30% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 31), oversold. The nearest support is the Pivot at $13.91, and the nearest resistance the Pivot R1 at $15.11.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 7.9%/day
Key levels
$21.2452 week high+52.6%
$18.14Swing high (Aug 13)+30.3%
$18.1250 day average+30.2%
$17.3020 day average+24.3%
$15.91100 day average+14.3%
$15.11Pivot R1+8.5%
$13.92Last close
$13.91Pivot−0.1%
$13.80200 day average−0.9%
$12.72Pivot S1−8.6%
$10.55Swing low (May 27)−24.2%
$6.7052 week low−51.9%
Indicators
RSI (14)30.76Weak, oversold below 30Neutral
MACD-0.45Below its signal lineBearish
Stochastic20.6Middle of its rangeNeutral
ADX (14)14.5No clear trend
Williams %R-81.6Oversold below −80, overbought above −20Oversold
CCI (20)-305.1Oversold below −100, overbought above 100Oversold
Rate of change−23.8%Change over 10 sessionsBearish
ATR (14)$1.10Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for OMER

What happened before

See how OMER did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OMER usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OMER has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Aug 20 – Aug 20
Loading…

See today’s whale options flow across the market →

OMER Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲103 buying vs 75 selling
  • ▲Held by funds +1.4 pts
  • ▲Funds holding +18
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding192174+10.3%
In funds' top 1032+50.0%
Held by funds55.8%54.3%+1.4 pts
New / increased41 / 6234 / 68+1.0%
Reduced / sold out50 / 2539 / 25+17.2%
Put/call ratio4.4412.31−63.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OMER institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OMER is in one of them and how their past OMER trades turned out.

OMER in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OMER in an article yet. Here's the latest on the wider market.

About Omeros

Omeros is a biotechnology company based in Seattle, Washington, that develops drugs aimed at the complement system, a part of the body's immune system. Its approved product, YARTEMLEA, treats thrombotic microangiopathy, a serious complication that can follow stem cell transplants, and it is sold for use in the United States. The company is also developing treatments for other immune conditions and for addiction. Its customers are patients and the hospitals and doctors who treat them.

Headquarters
Seattle, WA